Affimed Stock Jumps After Natural Killer Cells With AFM13 Show Clinical Responses, Minimal Toxicity

Loading...
Loading...
  • Affimed NV AFMD has announced initial clinical data from an investigator-sponsored study evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed's innate cell engager (ICE) AFM13 (CD16A/CD30).
  • The trial evaluates the pre-complexing of AFM13 with cbNK cells followed by three weekly infusions of AFM13 monotherapy in adult patients with recurrent/refractory CD30-positive lymphomas.
  • All four patients experienced significant disease reduction, with two complete responses and two partial responses as assessed by the investigator, with an objective response rate of 100%.
  • There were no observed events of cytokine release syndrome, neurotoxicity syndrome, or graft-versus-host disease.
  • The study is continuing enrollment of the second dose cohort.
  • The company will host a conference call/webcast on April 14 at 4:05 p.m. E.T.
  • Price Action: AFMD shares rise 40.8% at $11.05 in the premarket session on the last check Friday.
Posted In: BiotechNewsHealth CareSmall CapFDAGeneralBriefslymphoma
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...